Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Featured trial
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy

  • 160 views
  • 08 Nov, 2020
  • 1 location
Featured trial
  • 144 views
  • 25 Mar, 2021
  • 1 location
None
MPDL3280A-treatment-IST-UMCG

To be able to evaluate the investigational imaging - 89Zr-MPDL3280A-PET, 89Zr-CD8 imaging and 18F-FB-IL2-PET - as complementary tools for selection of patients to be treated with MPDL3280A

measurable disease
EGFR
epidermal growth factor
mpdl3280a
gefitinib
  • 6 views
  • 27 Jan, 2021
  • 1 location
None
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

without an actionable mutation will receive MPDL3280A (atezolizumab), a monoclonal antibody targeting anti-PDL1, as monotherapy or in combination with chemotherapy, The options for combination therapy

EGFR
mpdl3280a
pemetrexed
neutrophil count
metastasis
  • 6 views
  • 24 Jan, 2021
  • 1 location
None
Neoadjuvant Atezolizumab in Localized Bladder Cancer

This is a single arm, open label Phase II study of MPDL3280A, an anti-PD-L1 antibody administered as neoadjuvant therapy to subjects with either BCG-refractory non-muscle invasive transitional

carcinoma in situ
radical cystectomy
neutrophil count
metastasis
gilbert's syndrome
  • 8 views
  • 24 Jan, 2021
  • 3 locations
None
High-Risk Skin Cancers With Atezolizumab Plus NT-I7

The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

carcinoma
mek inhibitor
skin cancer
systemic therapy
metastatic melanoma
  • 14 views
  • 18 Aug, 2021
  • 8 locations
None
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

measurable disease
cancer treatment
solid tumor
lymphoma
monoclonal antibodies
  • 14 views
  • 01 Oct, 2021
  • 6 locations
None
A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

The yearly incidence of soft-tissue sarcomas (STS) in the USA is roughly 11,280 cases, and metastatic STS have a median overall survival of about 12 months. Sarcomas of the soft tissue are a heterogeneous group of malignant tumors of mesenchymal origin that originate in connective tissue. Local control with wide …

metastatic sarcoma
doxorubicin
measurable disease
immunomodulators
growth factor
  • 1 views
  • 26 Jan, 2021
  • 1 location